SCHEMBL674994

SCHEMBL674994

O=C(O)c1ccc2[nH]c3nccc(Cl)c3c2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 4/20 0.50
PTK6 Q13882 3/20 0.50
AURKB Q96GD4 2/20 0.48
AURKA O14965 1/20 0.48
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 1/20 0.47
THRB P10828 1/20 0.47
HPGD P15428 1/20 0.47
ALK Q9UM73 1/20 0.46
PTPN11 Q06124 1/20 0.43
DYRK1A Q13627 1/20 0.43
GSK3A P49840 2/20 0.42
GSK3B P49841 2/20 0.42
CDK5 Q00535 2/20 0.42
CDK5R1 Q15078 1/20 0.42
UTS2R Q9UKP6 1/20 0.41
CDC7 O00311 1/20 0.41
PLK4 O00444 1/20 0.41
CHEK1 O14757 1/20 0.41
MAPK13 O15264 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL676137 0.87 AURKA (0.50) ERBB2PTK6AURKBAURKAKDM4E
SCHEMBL6522132 0.85 AURKA (0.62) AURKBAURKAKDM4EDYRK1AMAPK13
SCHEMBL675910 0.84 PARP1 (0.46) ERBB2PTK6AURKBAURKAALK
SCHEMBL674216 0.83 ERBB2 (0.48) ERBB2PTK6AURKBAURKAKDM4E
SCHEMBL675341 0.83 TLR9 (0.50) ERBB2PTK6AURKBAURKAALDH1A1
SCHEMBL675507 0.82 ERBB2 (0.47) ERBB2PTK6AURKBAURKAKDM4E
SCHEMBL3669225 0.81 AURKA (0.47) ERBB2PTK6AURKBAURKAALK
SCHEMBL28603330 0.80 AURKA (0.49) ERBB2PTK6AURKAKDM4EALDH1A1
SCHEMBL675345 0.80 CA1 (0.47) ERBB2PTK6AURKBAURKAALDH1A1
SCHEMBL2014349 0.79 GABRP (0.52) ERBB2PTK6AURKBAURKAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895744-B2 Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) 2014-11-25 US disclosed
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) 2011-11-17 US disclosed
EP-2161271-A1 Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl Università Degli Studi Di Milano - Bicocca (IT) 2010-03-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL ALK, BCR, NPM1 ERBB2 156/4885PTK6 2466/4885AURKB 1300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.